Michael Barbella, Managing Editor06.06.23
Bausch + Lomb Corporation has welcomed two new members to its top management team, naming Bob Bailey as executive vice president and chief legal officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals. The pair replace Christina Ackermann, who was EVP, general counsel and president, Ophthalmic Pharmaceuticals, and has left the company.
“Bob Bailey and Andrew Stewart both bring more than 25 years of unrivaled leadership and expertise in their respective areas. Bob is a talented leader and legal strategist with experience that spans across the health care industry. Andrew has a highly proven track record of developing and commercializing pharmaceutical products that meet unmet needs in eye health,” Bausch + Lomb Chairman/CEO Brent Saunders said. “Having worked with Bob and Andrew for the past several years, I am confident they will create value for Bausch + Lomb and help position the company for long-term success. Additionally, I’d like to thank Christina Ackermann for her service and tireless dedication to the company. Under her leadership, Bausch + Lomb and its parent company successfully addressed a broad range of litigation, corporate, intellectual property and regulatory matters and expanded the depth of our Ophthalmic Pharmaceuticals portfolio.”
Bailey has more than 25 years of experience as a senior executive and over 15 years as a chief legal officer at private and publicly traded companies in the healthcare industry, including formerly serving as EVP, Law, Policy, and Communications at Bausch + Lomb from 2007 to 2013. He rejoins Bausch + Lomb from Datavant, a private health information technology company, where he most recently served as chief legal officer. Previously, he served as EVP, chief legal officer and corporate secretary of Allergan plc and its predecessor companies, Forest Laboratories Inc. and Actavis plc. At Allergan, he led a legal team that closed more than 20 public and private M&A transactions, as well as several licensing arrangements. During his career, he also has led teams that defended and resolved a range of complex legal and regulatory matters, including investigations by the U.S. Securities and Exchange Commission and the U.S. Department of Justice; internal investigations; and intellectual property, antitrust, commercial, product liability, and tax matters.
Bailey began his legal career as an attorney at Nixon Peabody LLP before moving to Bausch + Lomb in 1994. Until recently, Bailey served as a director of TearClear, an innovator in ophthalmic pharmaceuticals, and as a board member for the U.S. Chamber of Commerce Litigation Center.
Bailey earned his bachelor’s degree from St. Olaf College and his J.D. from the University of Minnesota.
“I am excited to return to Bausch + Lomb, where I served for 18 years earlier in my career,” Bailey said. “I look forward to working with this leadership team and my colleagues on the legal and compliance teams to contribute to the company’s future.”
Stewart has more than 25 years of experience in the pharmaceutical industry. He joins Bausch + Lomb from AbbVie, where he most recently served as general manager within the Eye Care franchise. At AbbVie and its predecessor company, Allergan plc, Stewart also previously had responsibility for the U.S. Retina business; led global marketing for the Eye Care franchise; and led business development initiatives for the Eye Care franchise. Earlier in his career, Stewart served at Bristol Meyers Squibb for nearly 14 years in Global Clinical Operations and Pharmaceutical Development Operations of the R&D department and at Merck & Co. Inc. for seven years in the manufacturing division.
Stewart earned an MBA from the New York University Stern School of Business, a master’s degree in environmental science from Rutgers University, and a bachelor’s degree in chemical engineering from the New Jersey Institute of Technology.
“Bausch + Lomb has a comprehensive product portfolio and innovative pipeline in Ophthalmic Pharmaceuticals,” Stewart stated. “I am eager to work with Brent and the team to bolster the company’s prescription medicines business and find new solutions that meet the evolving needs of the eye care professionals and patients around the world who rely on Bausch + Lomb.”
Bausch + Lomb protects and enhances sight for people worldwide. Its portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a global R&D, manufacturing, and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, N.J.
“Bob Bailey and Andrew Stewart both bring more than 25 years of unrivaled leadership and expertise in their respective areas. Bob is a talented leader and legal strategist with experience that spans across the health care industry. Andrew has a highly proven track record of developing and commercializing pharmaceutical products that meet unmet needs in eye health,” Bausch + Lomb Chairman/CEO Brent Saunders said. “Having worked with Bob and Andrew for the past several years, I am confident they will create value for Bausch + Lomb and help position the company for long-term success. Additionally, I’d like to thank Christina Ackermann for her service and tireless dedication to the company. Under her leadership, Bausch + Lomb and its parent company successfully addressed a broad range of litigation, corporate, intellectual property and regulatory matters and expanded the depth of our Ophthalmic Pharmaceuticals portfolio.”
Bailey has more than 25 years of experience as a senior executive and over 15 years as a chief legal officer at private and publicly traded companies in the healthcare industry, including formerly serving as EVP, Law, Policy, and Communications at Bausch + Lomb from 2007 to 2013. He rejoins Bausch + Lomb from Datavant, a private health information technology company, where he most recently served as chief legal officer. Previously, he served as EVP, chief legal officer and corporate secretary of Allergan plc and its predecessor companies, Forest Laboratories Inc. and Actavis plc. At Allergan, he led a legal team that closed more than 20 public and private M&A transactions, as well as several licensing arrangements. During his career, he also has led teams that defended and resolved a range of complex legal and regulatory matters, including investigations by the U.S. Securities and Exchange Commission and the U.S. Department of Justice; internal investigations; and intellectual property, antitrust, commercial, product liability, and tax matters.
Bailey began his legal career as an attorney at Nixon Peabody LLP before moving to Bausch + Lomb in 1994. Until recently, Bailey served as a director of TearClear, an innovator in ophthalmic pharmaceuticals, and as a board member for the U.S. Chamber of Commerce Litigation Center.
Bailey earned his bachelor’s degree from St. Olaf College and his J.D. from the University of Minnesota.
“I am excited to return to Bausch + Lomb, where I served for 18 years earlier in my career,” Bailey said. “I look forward to working with this leadership team and my colleagues on the legal and compliance teams to contribute to the company’s future.”
Stewart has more than 25 years of experience in the pharmaceutical industry. He joins Bausch + Lomb from AbbVie, where he most recently served as general manager within the Eye Care franchise. At AbbVie and its predecessor company, Allergan plc, Stewart also previously had responsibility for the U.S. Retina business; led global marketing for the Eye Care franchise; and led business development initiatives for the Eye Care franchise. Earlier in his career, Stewart served at Bristol Meyers Squibb for nearly 14 years in Global Clinical Operations and Pharmaceutical Development Operations of the R&D department and at Merck & Co. Inc. for seven years in the manufacturing division.
Stewart earned an MBA from the New York University Stern School of Business, a master’s degree in environmental science from Rutgers University, and a bachelor’s degree in chemical engineering from the New Jersey Institute of Technology.
“Bausch + Lomb has a comprehensive product portfolio and innovative pipeline in Ophthalmic Pharmaceuticals,” Stewart stated. “I am eager to work with Brent and the team to bolster the company’s prescription medicines business and find new solutions that meet the evolving needs of the eye care professionals and patients around the world who rely on Bausch + Lomb.”
Bausch + Lomb protects and enhances sight for people worldwide. Its portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a global R&D, manufacturing, and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, N.J.
